Bruker Acquires, Rebrands Dynamic Biosensors: Biophotonics Briefs: 10/2/24
MUNICH — Bruker acquired Dynamic Biosensors GmbH, a developer of single-cell interaction cytometry systems for drug discovery. Per the acquisition, Dynamic Biosensors will rebrand as Bruker Biosensors, and the transaction will add to Bruker’s biophysical portfolio for the analysis of molecular interactions and kinetics. This includes the heliXcyto, which performs single-cell interaction cytometry for kinetic measurements directly on cells. Dynamic Biosensors co-founders Ralf Strasser and Ulrich Rant will transition to the roles of managing director and CSO, respectively, of Bruker Biosensors.
The HeliX biosensor series, including the heliXcyto cytometer. Bruker acquired Dynamic Biosensors GmbH in a transaction that marks its eighth acquisition in the last year. Courtesy of Bruker.
DALLAS — Biotechnology company Nanoscope Therapeutics Inc. acquired a license for calcium-transporting channelrhodopsin (CatCh) technology from Max Planck Innovation, the technology transfer organization of the Max Planck Society. The CatCh technology enhances the light sensitivity of a multi-characteristic opsin (MCO-010) developed by Nanoscope as a gene therapy to restore vision in patients suffering from genetically caused visual impairments. Nanoscope has completed several clinical studies on MCO-010 for retinitis pigmentosa and Stargardt disease, and now plans to seek approval for the therapy and expand to broad therapeutic indications.
HAMBURG, Germany — Mindpeak, an AI-powered pathological solutions company, raised $15.3 million in a Series A funding round led by ZEISS Ventures and InnoVentureFund. The investment will enable the company to expand the commercialization of its technologies, including AI solutions and diagnostic tools that enable automated histological and immunohistochemical tissue analysis, across several geographies.
/Buyers_Guide/Bruker_Optics_Inc/c2051